Retraction
Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
Paper Information
Record ID:
46643
Author(s):
Publication Date:
October 13, 2021
Retraction Date:
June 21, 2023
(2.4 years years ago)
Subjects:
Broad Categories:
Medicine
Medicine
Institution:
Department of Pharmacy, Rizhao Central Hospital, No. 66, Wanghai Street, Rizhao City 276800, Shandong Province, ChinaCountry:
🇨🇳 ChinaArticle Type:
Publisher:
Hindawi
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1155/2023/9879023Additional Notes:
See also: https://pubpeer.com/publications/9762F9011D67577D13017160CFFFCD
Citations (7)
7
Total Citations2
Post-Retraction(28.6%)
4
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
0
Within 30 days
1
Within 1 year
0
After 2+ years
711
Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
Comparative Effectiveness of Paclitaxel‐Containing Regimens for Treatment of Triple‐Negative Breast Cancer: A Network Meta‐Analysis
Junqiang Niu, Xuan Tuo, Hui Xu et al. (9 authors)
Journal of Evidence-Based Medicine
Published: Jun 2025
711 days after retraction
Efficacy and safety of apatinib combined with dose‐dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis
Jiaxuan Liu, Maiyue He, Kaiping Ou et al. (14 authors)
International Journal of Cancer
Open Access
Published: Sep 2023
3 citations
3 citations
78 days after retraction
Case report: Apatinib combined with neoadjuvant therapy for primary squamous cell carcinoma of the breast: a case report
Fangfang Gao, Jingtai Li, Haoran Liao et al. (8 authors)
Frontiers in Pharmacology
Open Access
Published: May 2023
1 citation
1 citation
41 days before retraction
Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple‐Negative Breast Cancer
Evidence-Based Complementary and Alternative Medicine
Evidence-based Complementary and Alternative Medicine
Open Access
Published: Jan 2023
171 days before retraction
The correlation between neutrophil-to-lymphocyte ratio, carcinoembryonic antigen, and carbohydrate antigen 153 levels with chemotherapy-related cognitive impairment in early-stage breast cancer patients
Sheng Yu, Jingjing Zhao, Menglian Wang et al. (11 authors)
Frontiers in Medicine
Open Access
Published: Aug 2022
7 citations
7 citations
300 days before retraction
Association of Apatinib and Breast Cancer: A systematic review and meta-analysis
Hao Wang, Wanying Su, Scott Lowe et al. (14 authors)
Surgical Oncology
Published: Jul 2022
4 citations
4 citations
337 days before retraction
Quick Stats
Total Citations:
12
Years Since Retraction:
2.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025